© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Kodiak Sciences Inc. (KOD) stock declined over -2.06%, trading at $45.19 on NASDAQ, down from the previous close of $46.14. The stock opened at $46.85, fluctuating between $44.91 and $47.84 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 22, 2026 | 46.85 | 47.84 | 44.91 | 45.19 | 434.6K |
| Apr 21, 2026 | 46.50 | 46.96 | 45.30 | 46.14 | 559.91K |
| Apr 20, 2026 | 43.94 | 47.41 | 43.94 | 46.44 | 678.92K |
| Apr 17, 2026 | 42.35 | 45.61 | 41.00 | 44.90 | 1.04M |
| Apr 16, 2026 | 41.32 | 42.60 | 39.37 | 40.41 | 970.54K |
| Apr 14, 2026 | 42.42 | 45.39 | 42.33 | 45.07 | 1.34M |
| Apr 13, 2026 | 43.35 | 46.67 | 41.60 | 41.95 | 1.01M |
| Apr 10, 2026 | 42.64 | 43.95 | 41.74 | 43.11 | 737.46K |
| Apr 09, 2026 | 41.22 | 42.83 | 40.50 | 42.36 | 611.71K |
| Apr 08, 2026 | 43.00 | 43.99 | 40.92 | 41.80 | 891.74K |
| Apr 07, 2026 | 38.37 | 42.95 | 38.37 | 41.79 | 1.55M |
| Apr 06, 2026 | 40.18 | 41.93 | 38.80 | 39.00 | 989.46K |
| Apr 02, 2026 | 41.03 | 42.49 | 38.68 | 40.63 | 1.66M |
| Apr 01, 2026 | 39.78 | 44.30 | 38.22 | 42.81 | 2.61M |
| Mar 31, 2026 | 34.77 | 39.56 | 33.51 | 38.12 | 2.54M |
| Mar 30, 2026 | 37.54 | 37.60 | 33.35 | 33.66 | 2.34M |
| Mar 27, 2026 | 41.89 | 45.60 | 36.91 | 37.00 | 5.23M |
| Mar 25, 2026 | 21.88 | 23.62 | 21.42 | 22.75 | 757.49K |
| Mar 24, 2026 | 21.84 | 22.14 | 21.00 | 21.85 | 500.44K |
| Mar 23, 2026 | 22.75 | 23.75 | 21.90 | 22.24 | 467.75K |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, na�ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Employees | 109 |
| Beta | 2.4 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |